Investigation of Stent-grafts in Aortic Dissection (INSTEAD)

This study has been completed.
Sponsor:
Information provided by:
University of Rostock
ClinicalTrials.gov Identifier:
NCT01415804
First received: August 11, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

The objective of INSTEAD is to compare long-term (5 years) outcomes of endograft prosthesis versus medical management in patients with dissection of the thoracic aorta.


Condition Intervention Phase
Aortic Dissection
Device: endoprosthesis
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Comparison of Strategies for Type B Aortic Dissection - the INvestigation of STEnt-grafts in Aortic Dissection (INSTEAD) Trial

Further study details as provided by University of Rostock:

Primary Outcome Measures:
  • All cause mortality [ Time Frame: 5 years post randomization ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Aorta-specific mortality [ Time Frame: 5 years post randomization ] [ Designated as safety issue: Yes ]
  • Progression of disease [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Aortic remodeling [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: February 2002
Study Completion Date: March 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: stentgraft
Stentgraft
Device: endoprosthesis
Thoracic aortic stentgraft
Other Name: Talent endoprosthesis
No Intervention: Medical management
Antihypertensive medication
Device: endoprosthesis
Thoracic aortic stentgraft
Other Name: Talent endoprosthesis

Detailed Description:

Patients > 18 years with type B aortic dissection were randomized to either thoracic aortic endoprosthesis (stent-grafting) or antihypertensive management (medical treatment). Only stable patients without spontaneous false lumen thrombosis 14 days after index dissection were considered eligible for study inclusion. Long-term outcome measures included all-cause mortality, aorta-specific mortality and a cluster endpoint (reflecting progression of disease, conversion and additional interventions); the analysis is based on 140 randomized cases followed for at least 5 years.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • No contraindication the general anesthesia and ventilation
  • Type B aortic dissection that occurred 2-52 weeks prior to randomization
  • Diameter of the targeted aortic segment < 6 cm
  • Subject or legal guardian understand the nature of teh study and agrees to its provisions on a written informed consent form
  • Availability for appropriate follow-up visits during the F/U period of 5 years
  • Capability to follow all study requirements

Exclusion Criteria:

  • Pregnancy
  • Thrombocytopenia
  • Ongoing anticoagulation therapy
  • Renal failure and/or creatinine > 2,4 mg%
  • Complete thrombosis of false lumen
  • Cancer likely to cause death within 1 year
  • Enrollment in another clinical study
  • Unwillingness to cooperate with study procedures or F/U visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01415804

Locations
Germany
University Hospital Rostock; Heart Center
Rostock, MV, Germany, 18057
Sponsors and Collaborators
University of Rostock
Investigators
Principal Investigator: Christoph A Nienaber, MD University of Rostock
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Christoph A.Nienaber, MD, University of Rostock, Medical School; Dept. of Medicine/Cardiology
ClinicalTrials.gov Identifier: NCT01415804     History of Changes
Other Study ID Numbers: NCT00525356, INSTEAD 5 years outcomes
Study First Received: August 11, 2011
Last Updated: August 11, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration

Keywords provided by University of Rostock:
Dissection
Aorta
Surgery

ClinicalTrials.gov processed this record on September 18, 2014